Targeting EGFR Ex20 mutant lung cancer with the wild type sparing kinase inhibitor PRB001.

e14718Background: The majority of EGFR mutant tumors can be effectively treated with targeted drugs. Lung adenocarcinoma patients with EGFR Ex20 insertion mutations, however, lack safe and potent t...